{"canonical":"https://abierto.us/vendors/matrisome-bio-inc-dwr8lnqucjr8","key":"DWR8LNQUCJR8","name":"MATRISOME BIO, INC.","uei":"DWR8LNQUCJR8","city":"CAMBRIDGE","state":"MA","awards":1,"obligated":"299496.00","notices_won":0,"top_agency_name":"National Institutes of Health","top_naics":"541715","cage":"07E56","parent_name":"MATRISOME BIO, INC.","also_known_as":[],"country":"USA","actions":2,"first_action":"2025-09-11","last_action":"2026-09-10","breakdowns":{"naics":[{"key":"541715","name":null,"awards":1,"obligated":"299496.00"}],"places":[{"key":"MA","name":null,"awards":1,"obligated":"299496.00"}],"agencies":[{"key":"7529","name":"National Institutes of Health","awards":1,"obligated":"299496.00"}],"set_asides":[{"key":"SMALL BUSINESS SET ASIDE - TOTAL","name":null,"awards":1,"obligated":"299496.00"}],"award_types":[{"key":"DEFINITIVE CONTRACT","name":null,"awards":1,"obligated":"299496.00"}],"competition":[{"key":"FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES","name":null,"awards":1,"obligated":"299496.00"}],"product_service_codes":[{"key":"AN12","name":null,"awards":1,"obligated":"299496.00"}]},"awards_list":[{"award_key":"CONT_AWD_75N91025C00039_7529_-NONE-_-NONE-","permalink":"https://www.usaspending.gov/award/CONT_AWD_75N91025C00039_7529_-NONE-_-NONE-/","piid":"75N91025C00039","parent_piid":null,"award_type":"DEFINITIVE CONTRACT","vendor_key":"DWR8LNQUCJR8","recipient_name":"MATRISOME BIO, INC.","recipient_uei":"DWR8LNQUCJR8","recipient_cage":"07E56","recipient_city":"CAMBRIDGE","recipient_state":"MA","sub_name":"National Institutes of Health","office_name":"NIH NCI","office_key":"o-75N910","first_action_date":"2025-09-11","last_action_date":"2026-09-10","actions":2,"obligated":"299496.00","current_total_value":"299496.00","potential_total_value":"299496.00","naics":"541715","psc":"AN12","extent_competed":"FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES","set_aside":"SMALL BUSINESS SET ASIDE - TOTAL","offers_received":55,"description":"NOVEL THERANOSTIC RADIOLIGANDS TARGETING DISEASE-SPECIFIC EXTRACELLULAR MATRIX COMPONENTS SPECIFIC TO TUMOR AND METASTATIC LESIONS IN PATIENTS SUFFERING FROM HEREDITARY BREAST AND OVARIAN CANCER (HBOC)","method":null,"confidence":null,"evidence":null,"opportunity_key":null,"opportunity_title":null}],"awards_total":1,"awards_page":1,"won":[],"won_total":0,"solicitations_won":[]}